The structure is the story: Bayer keeps majority ownership and full operational control, and two of the largest alternative managers in the world provided capital rather than competing for the asset.
Apollo-managed funds and affiliates completed a 3 billion euro capital solution on Wednesday for a newly established entity holding Bayer's long-acting reversible contraceptives business, with KKR joining as what Apollo described as a "significant minority participant."
Bayer retains a majority stake in the new entity and full operational control. No change to the business's strategy was disclosed.
The transaction was first announced on July 10 as a possible Apollo-only arrangement. Wednesday's announcement is the closing, and it is the first disclosure of KKR's involvement.
Apollo Partner Jamshid Ehsani said the firm was "proud to serve as a capital partner to Bayer, originating and leading a multi-billion-euro capital solution tailored to their needs." Centerview Partners advised Apollo financially; Latham and Watkins, Paul, Weiss, Rifkind, Wharton and Garrison, and NautaDutilh acted as legal counsel.
Apollo Global Management shares (NYSE: APO) traded at $124.73 late Wednesday, down 1.79%, in line with a broad financials selloff that followed the Federal Reserve's rate decision.
What did not happen is the analytically important part
Bayer did not sell the business. It did not spin it off. It did not cede control.
It carved the division into a new legal entity, kept majority ownership and day-to-day operational authority, and sold a minority economic interest to private capital. That is a financing transaction wearing the clothing of a carve-out, and the distinction has consequences that a headline reading of "Apollo buys Bayer contraceptives unit" would get exactly backwards.
In a divestiture, the seller gives up the asset and receives cash. In this structure, Bayer receives capital while retaining the business, its future cash flows and the strategic flexibility that comes with control. What it gives up is a share of the economics and, presumably, some governance protections for its new partners, though the release does not describe any governance rights attaching to Apollo's or KKR's positions.
Two megafunds on the same side of a deal
The second structural feature worth flagging is that Apollo and KKR co-invested rather than competing.
In a conventional auction for a corporate carve-out, these two firms would be bidders against each other, and the outcome would be a change of control at a price set by that competition. Here they are jointly providing capital in a structure where nobody takes control. That reflects a category of transaction, corporate capital solutions, where the constraint is origination and structuring capability rather than the ability to win an auction.
The timing is worth noting. Structured minority capital becomes more attractive to corporate borrowers precisely when conventional debt gets more expensive, and the Fed spent Wednesday afternoon telling investors that borrowing costs are heading higher rather than lower.
The question the disclosure does not answer
What Bayer intends to do with the capital. The release does not address use of proceeds, and neither party has described the corporate rationale beyond Apollo's characterization of a solution tailored to Bayer's needs.
If this structure is a template that capital-constrained corporates can use to fund themselves without dismembering their portfolios, it is a meaningful development in how large-cap companies access private capital. If it reflects circumstances specific to Bayer's own balance sheet, it is a single transaction. Nothing disclosed on Wednesday distinguishes the two.
The specific equity split between Apollo and KKR was not disclosed, nor were target returns for either sponsor. Apollo separately stated a commitment to deploy more than $100 billion in Germany over the coming decade, a firm-level statement rather than a term of this transaction.